# nature research

Corresponding author(s):	David Singleton
Last updated by author(s):	Nov 18, 2020

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Sta	atistics		
For	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.	
n/a	Confirmed		
	<b>x</b> The exact	sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement	
×	A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly	
		tical test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.	
	X A descript	ion of all covariates tested	
	X A descript	ion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons	
	A full desc AND varia	cription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) tion (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)	
	For null hy	null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>P values as exact values whenever suitable.</i>	
×	For Bayes	ian analysis, information on the choice of priors and Markov chain Monte Carlo settings	
×	For hierar	complex designs, identification of the appropriate level for tests and full reporting of outcomes	
×	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated		
Our web collection on statistics for biologists contains articles on many of the points above.			
So	ftware an	d code	
Poli	cy information	about availability of computer code	
Da	ata collection	Data was stored in a SQL database, and queried via Microsoft SQL Server Management Studio 18.	
Da	ata analysis	R version 4.0.3 was used for all statistical analyses described in this study. R packages 'randomizr' (version 0.20.), 'plm' (version 2.2-5), 'gaplot2' (version 3.3.2), and 'rcompanion' (version 2.3.26) were also used.	

#### Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data that support the findings of this study are available from the corresponding author (DS) on reasonable request. The data are not publicly available due to them containing information that could compromise research participant privacy. Source data are provided with this paper.

### Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

The primary outcome was HPCIA prescription frequency post-intervention, compared to the CG. A sample size estimation indicated that to detect a 10% relative decrease in the primary outcome (standard deviation = 10%, power = 80% and α = 0.05), 17 practices would be required in each group.

Data exclusions

No data was excluded in this study.

Regression models were replicated 10,000 times, and convergence was assessed. Convergence was successfully achieved in all cases.

Randomization

60 practices were randomly and evenly allocated into three intervention groups: the control group (CG, n practices=20, sites=40), low group (LIG, n practices=20, sites=57) or high group (HIG, n practices=20, sites=51) by simple random allocation, utilising the 'complete random allocation' function available through the 'randomizr' R package.

Blinding

As this trial involved active and varying interventions between study groups, it was not possible to blind participants to the intervention they were receiving. However, participants were unaware of which other practices were involved in the trial, nor what interventions were being performed in opposing groups. The control group received no intervention, and was not aware of their involvement in the trial.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Ma	terials & experimental systems	Methods	
n/a	Involved in the study	n/a Involved in the study	
×	Antibodies	ChIP-seq	
×	Eukaryotic cell lines	Flow cytometry	
×	Palaeontology and archaeology	MRI-based neuroimaging	
×	Animals and other organisms	100 M	
×	Human research participants		
×	Clinical data		
×	Dual use research of concern		